FindTrial
Sign In

Atogepant 60 mg

DRUG8 trials

Sponsors

Allergan, AbbVie, University of Florence, IRCCS National Neurological Institute C. Mondino Foundation, Mayo Clinic

Conditions

Chronic MigraineEpisodic MigraineHeadacheHeadache (Migraine)MigraineMigraine DisabilityMigraine DiseaseMigraine Disorder

Phase 3

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
CompletedNCT03855137
AllerganChronic Migraine
Start: 2019-03-11End: 2022-01-20Updated: 2023-02-14
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
CompletedNCT04437433
AbbVieChronic Migraine, Episodic Migraine
Start: 2020-06-18End: 2024-06-11Updated: 2025-07-22
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
CompletedNCT04686136
AbbVieChronic Migraine, Episodic Migraine
Start: 2021-02-19End: 2025-10-20Updated: 2025-12-18
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
CompletedNCT04740827
AllerganEpisodic Migraine
Start: 2021-03-05End: 2022-08-04Updated: 2023-09-21

Phase 4

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RecruitingNCT06972056
Mayo ClinicMigraine
Start: 2025-07-09End: 2029-12-01Target: 1335Updated: 2026-06-29

Unknown Phase

Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
Active, not recruitingNCT06414044
University of FlorenceChronic Migraine, Migraine, Migraine With Aura +1
Start: 2024-05-09End: 2026-04-01Updated: 2026-01-21
Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
RecruitingNCT06882122
IRCCS National Neurological Institute C. Mondino FoundationEpisodic Migraine, Migraine Disorder
Start: 2024-12-01End: 2026-04-30Target: 30Updated: 2025-03-18
Long-term Atogepant in Real-world Practice
CompletedNCT07699549
Fundación de Investigación Biomédica - Hospital Universitario de La PrincesaHeadache, Headache (Migraine), Migraine +4
Start: 2024-06-01End: 2026-03-01Updated: 2026-07-13

Related Papers

SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study).
2026-06-26
The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability.
2026-03-25
Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study.
2026-03-11
Population Pharmacokinetics of Atogepant for the Prevention of Migraine.
2025-11-121 citations
Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine
Cephalalgia2025-08-01
Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study)
Cephalalgia2025-04-018 citations
Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials.
2025-02-011 citations
Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials.
2024-12-232 citations
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis
Cephalalgia2024-12-014 citations
Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials
Cephalalgia2024-12-012 citations
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial.
2024-06-2610 citations
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.
2024-02-1341 citations
Atogepant efficacy in people with chronic migraine with and without acute medication overuse: PROGRESS trial
2023-11-01
Effect of atogepant on patient reported outcomes in the preventive treatment of chronic migraine
2023-11-01
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
2023-07-2674 citations
Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial (S47.005)
Neurology2023-04-255 citations
Psychometric Evaluation of the Activity Impairment in Migraine-Diary (AIM-D) Using Data From a Phase 3 (PROGRESS) Clinical Trial in Patients With Chronic Migraine (P8-12.008)
Neurology2023-04-252 citations
Post Hoc Analysis of PROGRESS: Evaluating the Safety of Atogepant in Participants With Chronic Migraine and Cardiovascular Risk Factors (P10-12.012)
Neurology2023-04-252 citations
Psychometric Evaluation of the Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Using Data From Phase 3 Clinical Trials in Patients With Chronic Migraine (CM) and Episodic Migraine (EM) (P8-12.007)
Neurology2023-04-25
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.
2022-11-1719 citations